A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine

A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct...

Full description

Bibliographic Details
Main Authors: Alberto Muratorio, Ubaldo Bonuccelli, Angelo Nuti, Noe Bavpistini, Stefano Passero, Vittoria Caruso, Barbara Batani, Alberto Baroni, Federico Mayer, Tiziana Sorbi, Attilio Franciosi, Gianni Moro, Luciano Agostini, Massimo Piccirilli, Diana Scatozza
Format: Article
Language:Russian
Published: Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation 2018-07-01
Series:Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Subjects:
Online Access:https://www.bekhterevreview.com/jour/article/view/17
_version_ 1797694448852795392
author Alberto Muratorio
Ubaldo Bonuccelli
Angelo Nuti
Noe Bavpistini
Stefano Passero
Vittoria Caruso
Barbara Batani
Alberto Baroni
Federico Mayer
Tiziana Sorbi
Attilio Franciosi
Gianni Moro
Luciano Agostini
Massimo Piccirilli
Diana Scatozza
author_facet Alberto Muratorio
Ubaldo Bonuccelli
Angelo Nuti
Noe Bavpistini
Stefano Passero
Vittoria Caruso
Barbara Batani
Alberto Baroni
Federico Mayer
Tiziana Sorbi
Attilio Franciosi
Gianni Moro
Luciano Agostini
Massimo Piccirilli
Diana Scatozza
author_sort Alberto Muratorio
collection DOAJ
description A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct dementia. A 90-day treatment period with the test drug was followed by a 90-day follow-up period without treatment to observe how long the results obtained with treatment could be maintained. A total of 97 patients completed the treatment period; of these, 73 completed the follow-up period. Eighteen patients did not complete the study because of poor compliance, and 21 patients at one center were not followed up. Treatments were started after a 2-week washout period during which other drugs that could affect cognitive function were withdrawn. Clinical efficacy was evaluated by comparing the results at baseline, after 30 days, at the end of treatment, and at the end of the follow-up period on the following psychometric tests: the Sandoz Clinical Assessment Geriatric (SCAG) Rating Scale, the Blessed Dementia Scale, the Blessed Information, Memory, Concentration test, the Wechsler Memory Scale (WMS), the Rapid Disability Rating Scale 2 (RDRS 2), the Word Fluency test, the Token test, and the Simple Drawing Copy (SDC). The patients receiving L-a-GPC showed a significant improvement of cognitive functions, behaviour, and personality at the end of the treatment, compared with baseline values. This improvement was still apparent at the end of the follow-up period. A comparison of the results obtained with L-a-GPC and CDP-choline shows that the performance of the patients treated with L-a-GPC was significantly better than that of the CDP-choline group on the Blessed Dementia Scale, WMS, RDRS 2, and SDC at the end of treatment and on the Blessed Dementia Scale, WMS, SCAG, and Token test at the end of the follow-up period.
first_indexed 2024-03-12T02:58:07Z
format Article
id doaj.art-7f37ad910a314e839020d3852a333550
institution Directory Open Access Journal
issn 2313-7053
2713-055X
language Russian
last_indexed 2024-03-12T02:58:07Z
publishDate 2018-07-01
publisher Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation
record_format Article
series Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
spelling doaj.art-7f37ad910a314e839020d3852a3335502023-09-03T15:08:43ZrusFederal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian FederationОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева2313-70532713-055X2018-07-0102536017A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholineAlberto Muratorio0Ubaldo Bonuccelli1Angelo Nuti2Noe Bavpistini3Stefano Passero4Vittoria Caruso5Barbara Batani6Alberto Baroni7Federico Mayer8Tiziana Sorbi9Attilio Franciosi10Gianni Moro11Luciano Agostini12Massimo Piccirilli13Diana Scatozza14Istituto di Clinica Neurologica, Universita di PisaIstituto di Clinica Neurologica, Universita di PisaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeServizio di Neurologia, Ospedale Civile di ArzignanoServizio di Neurologia, Ospedale Civile di ArzignanoClinica Neurologica, Universita di PerugiaClinica Neurologica, Universita di PerugiaDirezione Medico Scientifica, Italfarmaco S.p.AA multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct dementia. A 90-day treatment period with the test drug was followed by a 90-day follow-up period without treatment to observe how long the results obtained with treatment could be maintained. A total of 97 patients completed the treatment period; of these, 73 completed the follow-up period. Eighteen patients did not complete the study because of poor compliance, and 21 patients at one center were not followed up. Treatments were started after a 2-week washout period during which other drugs that could affect cognitive function were withdrawn. Clinical efficacy was evaluated by comparing the results at baseline, after 30 days, at the end of treatment, and at the end of the follow-up period on the following psychometric tests: the Sandoz Clinical Assessment Geriatric (SCAG) Rating Scale, the Blessed Dementia Scale, the Blessed Information, Memory, Concentration test, the Wechsler Memory Scale (WMS), the Rapid Disability Rating Scale 2 (RDRS 2), the Word Fluency test, the Token test, and the Simple Drawing Copy (SDC). The patients receiving L-a-GPC showed a significant improvement of cognitive functions, behaviour, and personality at the end of the treatment, compared with baseline values. This improvement was still apparent at the end of the follow-up period. A comparison of the results obtained with L-a-GPC and CDP-choline shows that the performance of the patients treated with L-a-GPC was significantly better than that of the CDP-choline group on the Blessed Dementia Scale, WMS, RDRS 2, and SDC at the end of treatment and on the Blessed Dementia Scale, WMS, SCAG, and Token test at the end of the follow-up period.https://www.bekhterevreview.com/jour/article/view/17сосудистая деменциямультиинфарктная деменциянейропротективное действиекогнитивная функцияхолинацетилхолинхолина альфосцератvascular dementiamulti-infarct dementianeuroprotectiv actioncognitive functioncholineacetylcholinecholine alfostserat
spellingShingle Alberto Muratorio
Ubaldo Bonuccelli
Angelo Nuti
Noe Bavpistini
Stefano Passero
Vittoria Caruso
Barbara Batani
Alberto Baroni
Federico Mayer
Tiziana Sorbi
Attilio Franciosi
Gianni Moro
Luciano Agostini
Massimo Piccirilli
Diana Scatozza
A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
сосудистая деменция
мультиинфарктная деменция
нейропротективное действие
когнитивная функция
холин
ацетилхолин
холина альфосцерат
vascular dementia
multi-infarct dementia
neuroprotectiv action
cognitive function
choline
acetylcholine
choline alfostserat
title A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
title_full A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
title_fullStr A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
title_full_unstemmed A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
title_short A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
title_sort neurotropic approach to the treatment of multi infarct dementia using l a glycerylphosphorylcholine
topic сосудистая деменция
мультиинфарктная деменция
нейропротективное действие
когнитивная функция
холин
ацетилхолин
холина альфосцерат
vascular dementia
multi-infarct dementia
neuroprotectiv action
cognitive function
choline
acetylcholine
choline alfostserat
url https://www.bekhterevreview.com/jour/article/view/17
work_keys_str_mv AT albertomuratorio aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT ubaldobonuccelli aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT angelonuti aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT noebavpistini aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT stefanopassero aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT vittoriacaruso aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT barbarabatani aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT albertobaroni aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT federicomayer aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT tizianasorbi aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT attiliofranciosi aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT giannimoro aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT lucianoagostini aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT massimopiccirilli aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT dianascatozza aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT albertomuratorio neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT ubaldobonuccelli neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT angelonuti neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT noebavpistini neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT stefanopassero neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT vittoriacaruso neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT barbarabatani neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT albertobaroni neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT federicomayer neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT tizianasorbi neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT attiliofranciosi neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT giannimoro neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT lucianoagostini neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT massimopiccirilli neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine
AT dianascatozza neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine